- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00946335
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
Study Overview
Status
Conditions
- Recurrent Childhood Medulloblastoma
- Recurrent Childhood Ependymoma
- Childhood Atypical Teratoid/Rhabdoid Tumor
- Childhood Choroid Plexus Tumor
- Childhood Craniopharyngioma
- Childhood Ependymoblastoma
- Childhood Grade I Meningioma
- Childhood Grade II Meningioma
- Childhood Grade III Meningioma
- Childhood High-grade Cerebellar Astrocytoma
- Childhood High-grade Cerebral Astrocytoma
- Childhood Infratentorial Ependymoma
- Childhood Low-grade Cerebellar Astrocytoma
- Childhood Low-grade Cerebral Astrocytoma
- Childhood Medulloepithelioma
- Childhood Supratentorial Ependymoma
- Recurrent Childhood Brain Stem Glioma
- Recurrent Childhood Cerebellar Astrocytoma
- Recurrent Childhood Cerebral Astrocytoma
- Recurrent Childhood Pineoblastoma
- Recurrent Childhood Subependymal Giant Cell Astrocytoma
- Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
- Recurrent Childhood Visual Pathway and Hypothalamic Glioma
- Childhood Central Nervous System Germ Cell Tumor
- Childhood Mixed Glioma
- Childhood Oligodendroglioma
- Recurrent Childhood Spinal Cord Neoplasm
- Recurrent Childhood Brain Tumor
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To estimate the maximum tolerated dose (MTD) of ABT-888 in combination with temozolomide in children with recurrent or refractory CNS tumors.
II. To study the plasma pharmacokinetics (PK) of ABT-888 and PARP inhibition in peripheral blood mononuclear cells (PBMC) in order to recommend a Phase 2 dose of ABT-888 in combination with temozolomide in children with recurrent or refractory CNS tumors.
III. To describe the toxicities of the combination of ABT-888 and temozolomide in children with recurrent or refractory CNS tumors.
SECONDARY OBJECTIVES:
I. To measure non-homologous end-joining (NHEJ) activity in peripheral blood mononuclear cells (PBMC) prior to and following ABT-888 administration.
II. To assess PARP expression and/or activity in tumor tissue obtained at either initial diagnosis or relapse.
III. To determine expression and/or activity of DNA repair pathways, including MGMT and mismatch repair, in tumor tissues, when available.
IV. To document, within the confines of this phase 1 trial, radiographic tumor response to ABT-888 and temozolomide.
OUTLINE: This is a dose-escalation study of ABT-888.
Patients receive oral ABT-888 twice daily and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for 13-26 courses in the absence of disease progression or unacceptable toxicity.
Blood samples are collected for pharmacokinetics and further laboratory analysis.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- Pediatric Brain Tumor Consortium
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with a diagnosis of a primary CNS malignancy (including low-grade glioma) that is recurrent or refractory to standard therapy and for which there is no known curative therapy; all patients must have had histological verification of malignancy at initial diagnosis or relapse, excluding patients with diffuse intrinsic brain stem tumors, optic pathway tumors or CNS germ cell tumors with elevations of reliable serum or CSF tumor markers (alpha-fetoprotein or beta-HCG); patients with intrinsic pontine gliomas or optic pathway tumors do not require histological confirmation of disease but should have clinical and/or radiographic evidence of progression
- Patients must have Karnofsky Performance Score (for patients > 16 years of age) or Lansky Performance Score (for patients =< 16 years of age) >= 50% assessed within two weeks of study enrollment
- Patients must be able to take oral medications (either capsules or liquid); patients with neurologic deficits must have been stable for a minimum of 1 week prior to study entry; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
- Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study; recovery is defined as all AE"s, attributable to prior therapy, having improved to grade 2 or better or as outlined below
Myelosuppressive chemotherapy:
- Patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study registration
- Patients must have received their last dose of nitrosourea (including Gliadel) at least six (6) weeks prior to study registration
Biologic agent (anti-neoplastic): Patient must have received their last dose of other biologic agent ≥ 7 days prior to study registration
- For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair
- Monoclonal antibody treatment: Patient must have received their last dose of monoclonal antibody ≥ 4 weeks prior to registration
Radiation - Patients who have had prior radiation must have had their last fraction of:
- Craniospinal irradiation or total body irradiation > 3 months prior to registration
- Local irradiation to the primary tumors or other sites (cumulative dose ≥ 40Gy) > 3 months prior to registration
- Palliative irradiation delivered to symptomatic metastatic sites > 4 weeks prior to registration
Stem Cell Transplant: Patient must be:
- ≥ 6 months since allogeneic stem cell transplant prior to registration
- ≥ 3 months since autologous stem cell transplant prior to registration
- Corticosteroids: Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registration
Growth factors:
- Off all colony forming growth factor(s) that support platelet or white blood cell count, number or function for at least 1 week prior to registration (filgrastim, sargramostim, erythropoietin)
- Off Pegylated G-CSF and/or Erythropoiesis Stimulating Protein for at least 14 days prior to registration
- Temozolomide: Patients who have received temozolomide previously are eligible for this study if they meet all other inclusion and exclusion criteria
- Organ Function: Documented within 14 days of registration and within 7 days of starting treatment
- Hgb > 8 gm/dL (transfusion independent)
- Platelet count > 100,000/mm^3 (transfusion independent)
- Absolute neutrophil count (ANC) > 1, 500/mm^3
- Total Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 times institutional upper limit of normal (ULN) for age
- SGPT (ALT) ≤ 2.5 times institutional ULN for age
- Serum albumin ≥ 2 g/dL
Creatinine clearance or radioisotope GFR ≥ 70 ml/min/1.73m^2 or a serum creatinine based on age as follows:
- ≤ 5 years - 0.8 mg/dL maximum serum creatinine
- > 5 to ≤ 10 years - 1 mg/dL maximum serum creatinine
- > 10 to ≤ 15 years - 1.2 mg/dL maximum serum creatinine
- > 15 years - 1.5 maximum serum creatinine
- Patients must not be pregnant or breast-feeding; females of reproductive potential must have a negative serum or urine pregnancy test (within 72 hours prior to enrollment); males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method, which includes abstinence
- Signed informed consent which includes consent to participate in the REQUIRED pharmacokinetic and pharmacodynamic studies prior to registration
Exclusion Criteria:
Patients receiving any of the following medications are not eligible for study entry:
- Anti-cancer therapy
- Investigational agents
- Patients with any clinically significant, unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction), that would compromise the patient's ability to tolerate protocol therapy or would likely interfere with the study procedures or results
- Patients with uncontrolled seizures are not eligible for study entry
- Patients with inadequately controlled systemic hypertension (SBP and/or DBP > 95th percentile for age and height
- Patients with a prior history of hypertensive crisis and/or hypertensive encephalopathy
- If a BP measurement prior to registration is > 95th percentile for age and height, it must be rechecked and documented to be < 95th percentile for age and height prior to registration; if a patient falls between the height or weight percentiles, site should average the value as appropriate; for patients ≥ 18 years the normal blood pressure should be < 140/90 mm of Hg; patients with hypertension are eligible if their blood pressures become < 95th percentile for age and height after anti-hypertensive medications
- Patients with documented CNS ischemia and/or infarction, whether symptomatic or discovered incidentally without clinical symptoms, will be excluded from study participation
- Patients with an inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment (veliparib, temozolomide)
Patients receive oral ABT-888 twice daily and oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for 13-26 courses in the absence of disease progression or unacceptable toxicity. Blood samples are collected for pharmacokinetics and further laboratory analysis. |
Correlative studies
Correlative studies
Other Names:
Given PO
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Chronic toxicities
Time Frame: Up to 30 days post-treatment
|
Tabulated according to dose level and course of therapy.
|
Up to 30 days post-treatment
|
MTD or recommended phase II dose of veliparib
Time Frame: 28 days
|
28 days
|
|
Acute toxicities
Time Frame: Initial 4 weeks (course 1)
|
These toxicities will be tabulated according to dose level.
|
Initial 4 weeks (course 1)
|
Plasma drug concentrations and pharmacokinetic parameters, including volume of the central compartment (Vc/F), elimination rate constant (Ke), half-life (t1/2), apparent oral clearance (CL/F), and area under the plasma concentration time curve (AUC)
Time Frame: Baseline and during course 1
|
Presented in tabular and graphical form, and estimated using compartmental methods.
Dose proportionality in pharmacokinetic parameters will be investigated by performing one-way analysis of variance (ANOVA) on dose-normalized parameters.
|
Baseline and during course 1
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jack Su, Pediatric Brain Tumor Consortium
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Musculoskeletal Diseases
- Neoplasms, Neuroepithelial
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Spinal Cord Diseases
- Brain Neoplasms
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Bone Diseases
- Neoplasms, Complex and Mixed
- Neoplasms, Vascular Tissue
- Meningeal Neoplasms
- Bone Neoplasms
- Cerebral Ventricle Neoplasms
- Neoplasms
- Glioblastoma
- Recurrence
- Glioma
- Ependymoma
- Medulloblastoma
- Rhabdoid Tumor
- Astrocytoma
- Oligodendroglioma
- Meningioma
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Spinal Cord Neoplasms
- Pinealoma
- Craniopharyngioma
- Adamantinoma
- Choroid Plexus Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Temozolomide
- Veliparib
Other Study ID Numbers
- NCI-2012-03177 (REGISTRY: CTRP (Clinical Trial Reporting Program))
- U01CA081457 (U.S. NIH Grant/Contract)
- CDR649727
- PBTC-027 (OTHER: CTEP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Childhood Medulloblastoma
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Giant Cell Glioblastoma | Recurrent Childhood Glioblastoma | Recurrent Childhood Gliosarcoma | Recurrent Childhood OligodendrogliomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Ependymoma | Recurrent MedulloblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Childhood High-grade Cerebral Astrocytoma | Recurrent Childhood Brain Stem Glioma | Recurrent Childhood Cerebellar Astrocytoma | Recurrent Childhood Cerebral Astrocytoma | Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor | Recurrent Childhood... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood MedulloblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood MedulloblastomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Childhood Brain Stem Glioma | Childhood Spinal Cord Neoplasm | Childhood Oligodendroglioma | Childhood Cerebral Anaplastic AstrocytomaUnited States
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)TerminatedRecurrent Childhood Medulloblastoma | Childhood Choroid Plexus Tumor | Childhood Ependymoblastoma | Childhood Grade III Meningioma | Childhood High-grade Cerebellar Astrocytoma | Childhood High-grade Cerebral Astrocytoma | Childhood Medulloepithelioma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Childhood Rhabdomyosarcoma | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Recurrent Childhood Malignant Germ Cell Tumor | Recurrent... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGlioma | Recurrent Childhood Medulloblastoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Diffuse Intrinsic Pontine Glioma | Refractory Brain Neoplasm | Recurrent Childhood Anaplastic Oligodendroglioma | Recurrent Childhood Glioblastoma | Recurrent Primitive Neuroectodermal Tumor | Childhood Astrocytoma and other conditionsUnited States
-
Sabine Mueller, MD, PhDMayo Clinic; Vyriad, Inc.; No More Kids With Cancer; The Matthew Larson Foundation...CompletedMedulloblastoma Recurrent | Atypical Teratoid/Rhabdoid Tumor | Medulloblastoma, Childhood, RecurrentUnited States
Clinical Trials on laboratory biomarker analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)Recruiting
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingLynch Syndrome | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingRecurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingMalignant NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLung Cancer | Radiation Toxicity | Adult Brain TumorUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Askin TumorUnited States, Canada, Puerto Rico, Australia, New Zealand, Switzerland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed